Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04619082 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TAF to Prevent HBV Reactivation in Cancer Patients

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 12, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 31, 2023 to Dec 31, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 150 to confirmed 102
    • Site details revised at 5 of 5 sites
    v4
  2. Primary completion date: Dec 31, 2022 to Dec 31, 2023
    • Study completion date: Dec 31, 2023 to Dec 31, 2024
    • Start date: Jun 15, 2021 to Jul 1, 2021
    • Site details revised at 4 of 5 sites
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 1, 2020 to Jun 15, 2021
    • Site details revised at 5 of 5 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for cancer patients was lacing. Therefore, we conduct a prospective single arm study to evaluate the efficacy and safety of TAF as a prophylactic antiviral agent for HBsAg-positive cancer patients receiving chemotherapy.
Trial Details
NCT Number NCT04619082
Lead Sponsor Chiayi Christian Hospital
Collaborators: St. Martin De Porress Hospital, Dalin Tzu Chi General Hospital, National Taiwan University Hospital, Yun-Lin Branch, Chi Mei Medical Hospital
Conditions
(from sponsor)		 Hepatitis B Reactivation
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov